Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.

BACKGROUND Recognising colorectal cancer (CRC) patients with Lynch syndrome (LS) can increase life expectancy of these patients and their close relatives. To improve identification of this under-diagnosed disease, experts suggested raising the age limit for CRC tumour genetic testing from 50 to 70 years. The present study evaluates the efficacy and cost-effectiveness of this strategy. METHODS Probabilistic efficacy and cost-effectiveness analyses were carried out comparing tumour genetic testing of CRC diagnosed at age 70 or below (experimental strategy) versus CRC diagnosed at age 50 or below (current practice). The proportions of LS patients identified and cost-effectiveness including cascade screening of relatives, were calculated by decision analytic models based on real-life data. RESULTS Using the experimental strategy, four times more LS patients can be identified among CRC patients when compared with current practice. Both the costs to detect one LS patient (€9437/carrier versus €4837/carrier), and the number needed to test for detecting one LS patient (42 versus 19) doubled. When family cascade screening was included, the experimental strategy was found to be highly cost-effective according to Dutch standards, resulting in an overall ratio of €2703 per extra life-year gained in additionally tested patients. CONCLUSION Testing all CRC tumours diagnosed at or below age 70 for LS is cost-effective. Implementation is important as relatives from the large number of LS patients that are missed by current practice, can benefit from life-saving surveillance.

[1]  J. Balmaña,et al.  Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Marc S. Williams,et al.  Impact of age cutoffs on a lynch syndrome screening program. , 2013, Journal of oncology practice.

[3]  F. Nagengast,et al.  Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[4]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[5]  J. Stockman,et al.  Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer: A Cost-Effectiveness Analysis , 2013 .

[6]  J. Potter,et al.  Identification of Lynch syndrome among patients with colorectal cancer. , 2012, JAMA.

[7]  E. Kuipers,et al.  Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome , 2012, The Journal of pathology.

[8]  I. Nagtegaal,et al.  Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome. , 2011, European journal of cancer.

[9]  Heather Hampel,et al.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer , 2010, Genetics in Medicine.

[10]  Jukka-Pekka Mecklin,et al.  Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H T Lynch,et al.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.

[12]  Suet Yi Leung,et al.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[13]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Radvanyi,et al.  Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based Approach Versus Molecular Screening , 2008, The American Journal of Gastroenterology.

[15]  M. Ligtenberg,et al.  Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting , 2008, The American journal of surgical pathology.

[16]  A. W. Musschenga.  Zinnige en duurzame zorg , 2007 .

[17]  H. Meijers-Heijboer,et al.  Long Term Follow-up of HNPCC Gene Mutation Carriers: Compliance with Screening and Satisfaction with Counseling and Screening Procedures , 2005, Familial Cancer.

[18]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[19]  T. Ruers,et al.  Cost effectiveness of a new strategy to identify HNPCC patients , 2004, Gut.

[20]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[21]  A. Cats,et al.  Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect , 2003, Gut.

[22]  W. Zoller,et al.  [Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer]. , 2001, Zeitschrift fur Gastroenterologie.

[23]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[24]  Deborah Schrag,et al.  Benefits of Colonoscopic Surveillance and Prophylactic Colectomy in Patients with Hereditary Nonpolyposis Colorectal Cancer Mutations , 1998, Annals of Internal Medicine.

[25]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[26]  THE HAGUE-THE NETHERLANDS , 2022 .